Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasms 2Solid Tumor 1Neoplasm Metastasis 1

Interventions

pembrolizumab 134Gemcitabine 101Paclitaxel 100Carboplatin 85Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 58Pemetrexed 51Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × LY3022855 × Clear all
NCT02265536 2024-10-28

A Study of LY3022855 In Participants With Breast or Prostate Cancer

Eli Lilly and Company

Phase 1 Completed
34 enrolled 17 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01346358 2024-09-19

A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
52 enrolled 23 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡